Dazhi Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dazhi Sun has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Lijuan Xiu
4 shared publicationsXuan Liu
Department of Traditional Chinese Medicine Second Affiliated Hospital of Naval Medical University Shanghai China
4 shared publications- Xiaoqiang Yue
Department of Traditional Chinese Medicine, Changzheng Hospital, Naval Medical University, Shanghai, China
3 shared publications Bei Pei
2 shared publicationsJianpeng Jiao
2 shared publicationsJiaqi Du
Department of Anorectal, Shuguang Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
2 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- p. 026220244
Efficacy of a phlegm-resolving traditional Chinese medicine regimen in advanced gastric cancer: A retrospective observational study
Introduction: Traditional Chinese medicine has been shown to improve survival and immune function in patients with advanced gastric cancer (AGC). Objectives: This study aimed to evaluate the efficacy of a phlegm-resolving regimen (Ziyin Huatan recipe combined with Xiaoaiping injection) and syndrome differentiation-guided therapy combined with various antineoplastic Chinese patent medicine injections in AGC. Methods: Data from 150 patients with AGC were retrospectively analyzed: 75 in the study group and 75 in the control group. The clinical data were analyzed, including Karnofsky Performance Status (KPS), 1-, 2-, and 3-year survival rates, overall survival (OS), median OS, progression-free survival (PFS), and median PFS. Results: At 3 months, the mean KPS score significantly increased from 55.33 ± 6.44 to 73.07 ± 8.70 in the study group (p = 0.001 [< 0.01]), and from 54.93 ± 6.23 to 72.40 ± 8.67 (p = 0.001 [< 0.01]) in the control group. There was no significant difference in the changes of KPS score between the two groups. The median OS was 17.0 months in the study group (95% confidence interval [CI]: 13.16–20.84) versus 14.7 months in the control group (95% CI: 8.89–20.51). There was no significant difference in the OS between the two groups. The median PFS was 16.0 months in the study group (95% CI: 11.17–16.83) versus 12.0 months in the control group (95% CI: 7.48–16.52). The 1-year and 3-year PFS rates in the study group were higher than in the control group (61.33% versus 49.3% and 21.3% versus 14.7%, respectively). Conclusion: Our retrospective study suggests that phlegm-resolving regimens may confer survival benefits in patients with AGC; accordingly, such regimens can be considered for incorporation into standardized treatment strategies.
- 8 September 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- p. 026220244
Open AccessEfficacy of a phlegm-resolving traditional Chinese medicine regimen in advanced gastric cancer: A retrospective observational study
Introduction: Traditional Chinese medicine has been shown to improve survival and immune function in patients with advanced gastric cancer (AGC). Objectives: This study aimed to evaluate the efficacy of a phlegm-resolving regimen (Ziyin Huatan recipe combined with Xiaoaiping injection) and syndrome differentiation-guided therapy combined with various antineoplastic Chinese patent medicine injections in AGC. Methods: Data from 150 patients with AGC were retrospectively analyzed: 75 in the study group and 75 in the control group. The clinical data were analyzed, including Karnofsky Performance Status (KPS), 1-, 2-, and 3-year survival rates, overall survival (OS), median OS, progression-free survival (PFS), and median PFS. Results: At 3 months, the mean KPS score significantly increased from 55.33 ± 6.44 to 73.07 ± 8.70 in the study group (p = 0.001 [< 0.01]), and from 54.93 ± 6.23 to 72.40 ± 8.67 (p = 0.001 [< 0.01]) in the control group. There was no significant difference in the changes of KPS score between the two groups. The median OS was 17.0 months in the study group (95% confidence interval [CI]: 13.16–20.84) versus 14.7 months in the control group (95% CI: 8.89–20.51). There was no significant difference in the OS between the two groups. The median PFS was 16.0 months in the study group (95% CI: 11.17–16.83) versus 12.0 months in the control group (95% CI: 7.48–16.52). The 1-year and 3-year PFS rates in the study group were higher than in the control group (61.33% versus 49.3% and 21.3% versus 14.7%, respectively). Conclusion: Our retrospective study suggests that phlegm-resolving regimens may confer survival benefits in patients with AGC; accordingly, such regimens can be considered for incorporation into standardized treatment strategies.
- Open Access
- 18 September 2023
- Published by Wiley in Precision Medical Sciences
- Vol. 12 (4) , 253-259
Xiaotan Sanjie Fang prevents colonic inflammation‐related tumorigenesis by inhibiting COX‐2/VEGF expression cancer
- 18 September 2023
- Published by Wiley in Precision Medical Sciences
- Vol. 12 (4) , 253-259
Open AccessXiaotan Sanjie Fang prevents colonic inflammation‐related tumorigenesis by inhibiting COX‐2/VEGF expression cancer
- Open Access
- 30 August 2022
- Published by Wiley in Environmental Toxicology
- Vol. 37 (12) , 2957-2964
Xiaotansanjiefang inhibits the viability of colorectal cancer cells via Jagged 1/Notch 3/Snail signaling pathway
The purpose of this study is to explore the anti‐colorectal cancer of Xiaotansanjiefang, a famous traditional Chinese medicine, and its potential anti‐cancer mechanism. In this study, the HCT116 cell spheres were prepared as in vitro study model. We found the Xiaotansanjiefang medication was able to inhibit the proliferation of HCT116 cell spheres in a dose‐dependent manner, especially in 3 and 6 mg/ml Xiaotansanjiefang medication treated groups. We also found the high concentration of Xiaotansanjiefang medication could suppress the migration and promote the apoptosis of HCT116 cell spheres. Moreover, we found the expression of Jagged 1, Notch 3, Snail, and Hes 1 were decreased in HCT116 cell spheres treated with Xiaotansanjiefang medication. Furthermore, the proliferation and apoptosis behaviors of HCT116 cell spheres treated with Xiaotansanjiefang medication were reversed with the addition of Jagged 1 Fc chimera protein. The expression of Jagged 1, Notch 3, Snail, and Hes 1 were also increased again in HCT116 cells treated with Xiaotansanjiefang medication plus with Jagged 1 Fc chimera protein. The presented study may provide a promising strategy to treat and prevent colorectal cancer.
- 30 August 2022
- Published by Wiley in Environmental Toxicology
- Vol. 37 (12) , 2957-2964
Open AccessXiaotansanjiefang inhibits the viability of colorectal cancer cells via Jagged 1/Notch 3/Snail signaling pathway
The purpose of this study is to explore the anti‐colorectal cancer of Xiaotansanjiefang, a famous traditional Chinese medicine, and its potential anti‐cancer mechanism. In this study, the HCT116 cell spheres were prepared as in vitro study model. We found the Xiaotansanjiefang medication was able to inhibit the proliferation of HCT116 cell spheres in a dose‐dependent manner, especially in 3 and 6 mg/ml Xiaotansanjiefang medication treated groups. We also found the high concentration of Xiaotansanjiefang medication could suppress the migration and promote the apoptosis of HCT116 cell spheres. Moreover, we found the expression of Jagged 1, Notch 3, Snail, and Hes 1 were decreased in HCT116 cell spheres treated with Xiaotansanjiefang medication. Furthermore, the proliferation and apoptosis behaviors of HCT116 cell spheres treated with Xiaotansanjiefang medication were reversed with the addition of Jagged 1 Fc chimera protein. The expression of Jagged 1, Notch 3, Snail, and Hes 1 were also increased again in HCT116 cells treated with Xiaotansanjiefang medication plus with Jagged 1 Fc chimera protein. The presented study may provide a promising strategy to treat and prevent colorectal cancer.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 99-110
Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity
Background and Objective: Neurotoxicity is a common side effect of oxaliplatin; the effect of current drugs such as methylcobalamin and gabapentine is not obvious. Astragaloside IV (AS-IV) is an important active ingredient of Astragali Radix, which can protect the nervous system and inhibit tumor growth to a certain extent. However, whether AS-IV can reduce oxaliplatin neurotoxicity and its molecular mechanism remain unclear. Methods: The network pharmacology method was used to determine the collective targets of AS-IV and oxaliplatin neurotoxicity. The model of neurotoxicity was established by intraperitoneal injection of oxaliplatin in rats. Bodyweight, mechanical withdrawal threshold (MWT), cold allodynia, and nerve conduction velocity (NCV) were examined, pathological changes were observed by hematoxylin-eosin staining, number of Nissl bodies were assessed by Nissl staining, the key collective targets were measured by spectrophotometry and immunohistochemistry. Results: Through network pharmacological analysis, 25 collective targets of AS-IV and oxaliplatin neurotoxicity were identified, mainly related to inflammation and oxidative stress. AS-IV could increase body weight, elevate MWT, and reduce cold allodynia of model rats, it also raised NCV. Neuropathology was improved and the number of Nissl bodies was increased by AS-IV administration. It reduced TNF-α, IL-6, and IL-1β in the spinal cord of model rats to inhibit inflammation; it also decreased MDA, raised SOD, CAT, and GSH-Px in the spinal cord of model rats to block oxidative stress. Conclusion: AS-IV improves oxaliplatin neurotoxicity by regulating neuroinflammation and oxidative stress; the results can provide a new perspective for the potential treatment strategy of oxaliplatin neurotoxicity.
- 1 January 2021
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 99-110
Open AccessNetwork Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity
Background and Objective: Neurotoxicity is a common side effect of oxaliplatin; the effect of current drugs such as methylcobalamin and gabapentine is not obvious. Astragaloside IV (AS-IV) is an important active ingredient of Astragali Radix, which can protect the nervous system and inhibit tumor growth to a certain extent. However, whether AS-IV can reduce oxaliplatin neurotoxicity and its molecular mechanism remain unclear. Methods: The network pharmacology method was used to determine the collective targets of AS-IV and oxaliplatin neurotoxicity. The model of neurotoxicity was established by intraperitoneal injection of oxaliplatin in rats. Bodyweight, mechanical withdrawal threshold (MWT), cold allodynia, and nerve conduction velocity (NCV) were examined, pathological changes were observed by hematoxylin-eosin staining, number of Nissl bodies were assessed by Nissl staining, the key collective targets were measured by spectrophotometry and immunohistochemistry. Results: Through network pharmacological analysis, 25 collective targets of AS-IV and oxaliplatin neurotoxicity were identified, mainly related to inflammation and oxidative stress. AS-IV could increase body weight, elevate MWT, and reduce cold allodynia of model rats, it also raised NCV. Neuropathology was improved and the number of Nissl bodies was increased by AS-IV administration. It reduced TNF-α, IL-6, and IL-1β in the spinal cord of model rats to inhibit inflammation; it also decreased MDA, raised SOD, CAT, and GSH-Px in the spinal cord of model rats to block oxidative stress. Conclusion: AS-IV improves oxaliplatin neurotoxicity by regulating neuroinflammation and oxidative stress; the results can provide a new perspective for the potential treatment strategy of oxaliplatin neurotoxicity.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 4129461
Xiaotan Jieyu Prescription Alleviates Breast Precancerous Lesions through PI3K/Akt Signaling Pathway
Background/Aims. In previous studies, it has been observed that Xiaotan Jieyu (XTJY) prescription may inhibit the proliferation of human breast precancerous lesion MCF‐10AT cells by inhibiting the PI3K/Akt signaling pathway. The purpose of this study is to further verify the therapeutic effect and the possible mechanism of XTJY on precancerous lesions of breast cancer in vivo. Methods. The successfully established breast precancerous lesion rat model and normal healthy rats were randomly assigned into the blank (BLA), model (MOD), XTJY‐low (LD), XTJY‐medium (MD), XTJY‐high (HD), and tamoxifen (TAM) groups. Different concentrations of XTJY and saline were supplied by intragastric administration for 4 consecutive weeks to assess the protective effect of XTJY on the progress of the breast precancerous lesion in rats involving the phosphatidylinositol‐3‐kinase (PI3K)/protein kinase B (Akt) signaling pathway. Results. In this study, it determined that 10 mg/each rat DMBA‐combined estrogen and progesterone induction for 10 weeks was the optimal condition for the establishment of the breast precancerous lesion rat model. In vivo administration of XTJY or TAM was found to inhibit the development of the breast precancerous lesion, and the occurrence rate of breast invasive carcinomas was decreased by about 50%. Furthermore, XTJY or TAM markedly reduced protein expressions of PI3K and p‐Akt and increased protein expressions of PTEN. Conclusion. These data indicated that XTJY can significantly alleviate the development of breast precancerous lesions by inhibiting the activation of the PI3K/Akt signaling pathway. XTJY may be a promising drug for the treatment of precancerous lesions in breast cancer.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 4129461
Open AccessXiaotan Jieyu Prescription Alleviates Breast Precancerous Lesions through PI3K/Akt Signaling Pathway
Background/Aims. In previous studies, it has been observed that Xiaotan Jieyu (XTJY) prescription may inhibit the proliferation of human breast precancerous lesion MCF‐10AT cells by inhibiting the PI3K/Akt signaling pathway. The purpose of this study is to further verify the therapeutic effect and the possible mechanism of XTJY on precancerous lesions of breast cancer in vivo. Methods. The successfully established breast precancerous lesion rat model and normal healthy rats were randomly assigned into the blank (BLA), model (MOD), XTJY‐low (LD), XTJY‐medium (MD), XTJY‐high (HD), and tamoxifen (TAM) groups. Different concentrations of XTJY and saline were supplied by intragastric administration for 4 consecutive weeks to assess the protective effect of XTJY on the progress of the breast precancerous lesion in rats involving the phosphatidylinositol‐3‐kinase (PI3K)/protein kinase B (Akt) signaling pathway. Results. In this study, it determined that 10 mg/each rat DMBA‐combined estrogen and progesterone induction for 10 weeks was the optimal condition for the establishment of the breast precancerous lesion rat model. In vivo administration of XTJY or TAM was found to inhibit the development of the breast precancerous lesion, and the occurrence rate of breast invasive carcinomas was decreased by about 50%. Furthermore, XTJY or TAM markedly reduced protein expressions of PI3K and p‐Akt and increased protein expressions of PTEN. Conclusion. These data indicated that XTJY can significantly alleviate the development of breast precancerous lesions by inhibiting the activation of the PI3K/Akt signaling pathway. XTJY may be a promising drug for the treatment of precancerous lesions in breast cancer.
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 2018162
ZiYinHuaTan Recipe Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer by Suppressing PI3K/AKT Pathway
In recent years, traditional Chinese medicine has played an important role in the treatment of gastric cancer in China. ZiYinHuaTan (ZYHT) recipe was developed for advanced gastric cancer and had shown its promising value in the clinic. In this study, we explore the effect of ZYHT on gastric cancer in vitro and in vivo. ZYHT can inhibit tumor growth and improve the general condition of mice in subcutaneous transplantation nude mice models of gastric cancer. And ZYHT can also inhibit cell proliferation and blocked the cells in G0/G1 to induce cell apoptosis in HGC27 and MGC803 cells. Then, network pharmacology analysis showed that ZYHT may exert antitumor effect mainly through PI3K/AKT signaling pathway. Furthermore, the expression of PI3K, p‐Akt, CyclinD1, and Bcl‐2 was detected in vitro and in vivo. The results showed that ZYHT could decrease the expression of PI3K, CyclinD1, and Bcl‐2 both in vitro and in vivo. These results suggested that ZYHT could be used as a method for the treatment of developed gastric cancer.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 2018162
Open AccessZiYinHuaTan Recipe Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer by Suppressing PI3K/AKT Pathway
In recent years, traditional Chinese medicine has played an important role in the treatment of gastric cancer in China. ZiYinHuaTan (ZYHT) recipe was developed for advanced gastric cancer and had shown its promising value in the clinic. In this study, we explore the effect of ZYHT on gastric cancer in vitro and in vivo. ZYHT can inhibit tumor growth and improve the general condition of mice in subcutaneous transplantation nude mice models of gastric cancer. And ZYHT can also inhibit cell proliferation and blocked the cells in G0/G1 to induce cell apoptosis in HGC27 and MGC803 cells. Then, network pharmacology analysis showed that ZYHT may exert antitumor effect mainly through PI3K/AKT signaling pathway. Furthermore, the expression of PI3K, p‐Akt, CyclinD1, and Bcl‐2 was detected in vitro and in vivo. The results showed that ZYHT could decrease the expression of PI3K, CyclinD1, and Bcl‐2 both in vitro and in vivo. These results suggested that ZYHT could be used as a method for the treatment of developed gastric cancer.